Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease which results in end-stage fibrosis. The pathogenesis is believed to be related to a dysregulation in cross-talk between inflammatory and structural cells, mediated by various cytokines, chemokines and growth factors, which are responsible for the maintenance of tissue homeostasis and which coordinate the response to injury. The large number of mediators involved and the complexity of their interaction makes it difficult to identify the factors responsible for initiation of fibrogenesis and progression to chronicity. Whether a mediator ’ s presence in fibrotic lung is as a result of tissue injury or if it playsan active role in disease onset and progression has been partly answered by the use of transient and / or permanent transgenic and gene knock-out approaches to over-express single factors at a time. Chemokines such as interleukin-8 (IL-8), RANTES, IP-10, MIG or lymphotactin, do not appear to induce fibrosis when over-expressed in rodent lung. Amongst many tested, four cytokines and growth factors have been found to be pro-fibrotic; IL-1β, which demonstrates marked inflammation, tissue damage and chronic fibrosis, TNF-?, which induces inflammation and mild fibrosis, and GM-CSF, which induces moderate inflammation and fibrosis. A common finding with these cytokines are increased lung TGF-β levels, proportionate to the degree of fibrosis generated, while TGF-β itself causes minor inflammation but marked progressive chronic fibrosis. A growth factor ‘downstream’ from the pro-fibrotic effects of TGF-β, CTGF, is a likely critical mediator. However, over-expression of CTGF produces only mild and reversible fibrosis.
Keywords: Fibrogenic Cytokines, cytokines, RANTES, lymphotactin, homeostasis
Current Pharmaceutical Design
Title: Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis
Volume: 9 Issue: 1
Author(s): Margaret Kelly, Martin Kolb, Phillipe Bonniaud and Jack Gauldie
Affiliation:
Keywords: Fibrogenic Cytokines, cytokines, RANTES, lymphotactin, homeostasis
Abstract: Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease which results in end-stage fibrosis. The pathogenesis is believed to be related to a dysregulation in cross-talk between inflammatory and structural cells, mediated by various cytokines, chemokines and growth factors, which are responsible for the maintenance of tissue homeostasis and which coordinate the response to injury. The large number of mediators involved and the complexity of their interaction makes it difficult to identify the factors responsible for initiation of fibrogenesis and progression to chronicity. Whether a mediator ’ s presence in fibrotic lung is as a result of tissue injury or if it playsan active role in disease onset and progression has been partly answered by the use of transient and / or permanent transgenic and gene knock-out approaches to over-express single factors at a time. Chemokines such as interleukin-8 (IL-8), RANTES, IP-10, MIG or lymphotactin, do not appear to induce fibrosis when over-expressed in rodent lung. Amongst many tested, four cytokines and growth factors have been found to be pro-fibrotic; IL-1β, which demonstrates marked inflammation, tissue damage and chronic fibrosis, TNF-?, which induces inflammation and mild fibrosis, and GM-CSF, which induces moderate inflammation and fibrosis. A common finding with these cytokines are increased lung TGF-β levels, proportionate to the degree of fibrosis generated, while TGF-β itself causes minor inflammation but marked progressive chronic fibrosis. A growth factor ‘downstream’ from the pro-fibrotic effects of TGF-β, CTGF, is a likely critical mediator. However, over-expression of CTGF produces only mild and reversible fibrosis.
Export Options
About this article
Cite this article as:
Kelly Margaret, Kolb Martin, Bonniaud Phillipe and Gauldie Jack, Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis, Current Pharmaceutical Design 2003; 9 (1) . https://dx.doi.org/10.2174/1381612033392341
DOI https://dx.doi.org/10.2174/1381612033392341 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS
Current Pharmaceutical Biotechnology Structural Aspects of Peptides with Immunomodulating Activity
Mini-Reviews in Medicinal Chemistry Early Postoperative Bleeding in Polytrauma Patients Treated with Fondaparinux: Literature Review and Institutional Experience
Current Vascular Pharmacology A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
Current Pharmaceutical Design Charcot Neuroarthropathy: From the Laboratory to the Bedside
Current Diabetes Reviews DNA Topoisomerases in Life and Death: Implications in Kinetoplastid Protozoa
Current Molecular Medicine Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry A Multiple-Dose, Open-Label, Safety, Compliance, and Usage Evaluation Study of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome®) in Joint/Musculoskeletal Pain or Soft Tissue Inflammation
Current Drug Safety Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma
Combinatorial Chemistry & High Throughput Screening Current Status and Advances in Severe Drug Hypersensitivity Reactions
Current Pharmaceutical Design Can Soy Prevent Male Osteoporosis? A Review of the Current Evidence
Current Drug Targets VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery An Insight into Hepatitis C Virus: In Search of Promising Drug Targets
Current Drug Targets Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
Current Pharmaceutical Biotechnology Are Chemically Reactive Metabolites Responsible for Adverse Reactions to Drugs?
Current Drug Metabolism Antiviral Activity of Phytochemicals: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Editorial: Protein Kinases and their Inhibitors
Current Enzyme Inhibition